An article in Nature.com reinforces the suggestion in my previous post – namely that it is possible our industry may emerge healthier post-COVID-19 than before. Yes, we have seen massive drop-offs in patient uptake of trials, but some out there have been innovating, and attempting to develop new approaches to patient participation. Katherine Tuttle talks about herContinue reading “Impact of the COVID-19 pandemic on clinical research”
Category Archives: Uncategorized
Who should get the jab?
As usual from the Economist and insightful assessment of some aspects of the roll out of the vaccine which will be our focus in 2021 https://amp.economist.com/leaders/2021/01/09/who-should-get-the-jab
How COVID‑19 has impacted the clinical trials sector
EY has published an interesting article discussing the opinions of the participants of the EY Virtual Clinical Trials roundtable, looking at the impact that COVID-19 has had on the clinical trials sector. The key to many of these trials is the availability of both staff to carry out the work, and patients to take partContinue reading “How COVID‑19 has impacted the clinical trials sector”
Bio Pharma Consulting 